Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Mar;17(3):189-200.
doi: 10.1080/14787210.2019.1577136. Epub 2019 Feb 18.

Ocular Chlamydia trachomatis infection: elimination with mass drug administration

Affiliations
Review

Ocular Chlamydia trachomatis infection: elimination with mass drug administration

Meraf A Wolle et al. Expert Rev Anti Infect Ther. 2019 Mar.

Abstract

Ocular Chlamydia trachomatis infection, the causative agent for trachoma, is responsible for 1.9 million cases of visual loss worldwide. Mass Drug Administration (MDA) with azithromycin to entire trachoma-endemic districts is part of the World Health Organization's public health strategy for trachoma elimination. Areas covered: Background on C. trachomatis and the epidemiology of trachoma are presented, followed by a review of the antibiotics for treatment and the need for a public health approach to trachoma elimination. The effectiveness of mass drug administration is presented, concluding with challenges to trachoma elimination in the future. Expert opinion: MDA using azithromycin is a key component of the public health strategy for trachoma elimination. With high coverage in children, there is good evidence that MDA drops the community pool of infection. There are challenges to trachoma elimination by the year 2020, and the drug donation program for country MDAs will be integral to ongoing efforts.

Keywords: azithromycin; mass drug administration; review; trachoma.

PubMed Disclaimer

Conflict of interest statement

Declaration of interest

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Figures

Figure 1.
Figure 1.
Images of A) Trachoma-Follicular (TF), B) Trachoma –Intense (TI), C) Trachomatous scarring (TS) and D) Trachomatous Trichiasis (TT) (images collected by SW and MW during field work).

Similar articles

Cited by

References

    1. World Health Organization. Global Elimination of Blinding Trachoma. In: World Health Assembly, editor. WHA5111 1998.
    1. Elwell C, Mirrashidi K, Engel J. Chlamydia cell biology and pathogenesis. Nature reviews Microbiology. 2016;14(6):385–400. Epub 2016/04/26. doi: 10.1038/nrmicro.2016.30. - DOI - PMC - PubMed
    2. An excellent review of chlamydia cell biology, for further details at the basic science level

    1. Witkin SS, Minis E, Athanasiou A, Leizer J, Linhares IM. Chlamydia trachomatis: the Persistent Pathogen. Clinical and vaccine immunology : CVI. 2017;24(10). Epub 2017/08/25. doi: 10.1128/cvi.00203-17. - DOI - PMC - PubMed
    1. Elwell CA, Czudnochowski N, von Dollen J, Johnson JR, Nakagawa R, Mirrashidi K, et al. Chlamydia interfere with an interaction between the mannose-6-phosphate receptor and sorting nexins to counteract host restriction. eLife. 2017;6 Epub 2017/03/03. doi: 10.7554/eLife.22709. - DOI - PMC - PubMed
    1. Caldwell HD, Wood H, Crane D, Bailey R, Jones RB, Mabey D, et al. Polymorphisms in Chlamydia trachomatis tryptophan synthase genes differentiate between genital and ocular isolates. The Journal of clinical investigation. 2003;111(11):1757–69. Epub 2003/06/05. doi: 10.1172/jci17993. - DOI - PMC - PubMed
    2. An article that lays out how the biovars may differ, and explains the tissue tropism

Publication types

MeSH terms